HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Protagonist Therapeutics and raised the price target from $40 to $50, indicating confidence in the company's future performance.
September 12, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Protagonist Therapeutics and increased the price target from $40 to $50, suggesting a positive outlook for the company's stock.
The increase in the price target from $40 to $50 by HC Wainwright & Co. reflects a strong positive sentiment towards Protagonist Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100